Literature DB >> 30080177

Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.

Changshan Wang1,2, Motohiko Oshima2, Daisuke Sato2, Hirotaka Matsui3, Sho Kubota4, Kazumasa Aoyama2, Yaeko Nakajima-Takagi2, Shuhei Koide2, Jun Matsubayashi5, Makiko Mochizuki-Kashio2, Takako Nakano-Yokomizo4, Jie Bai4, Toshitaka Nagao5, Akinori Kanai6, Atsushi Iwama2,7, Goro Sashida2,4.   

Abstract

Early T cell precursor acute lymphoblastic leukemia (ETP-ALL) is a new pathological entity with poor outcomes in T cell ALL (T-ALL) that is characterized by a high incidence of loss-of-function mutations in polycomb repressive complex 2 (PRC2) genes. We generated a mouse model of ETP-ALL by deleting Ezh2, one of the PRC2 genes, in p53-null hematopoietic cells. The loss of Ezh2 in p53-null hematopoietic cells impeded the differentiation of ETPs and eventually induced ETP-ALL-like disease in mice, indicating that PRC2 functions as a bona fide tumor suppressor in ETPs. A large portion of PRC2 target genes acquired DNA hypermethylation of their promoters following reductions in H3K27me3 levels upon the loss of Ezh2, which included pivotal T cell differentiation-regulating genes. The reactivation of a set of regulators by a DNA-demethylating agent, but not the transduction of single regulator genes, effectively induced the differentiation of ETP-ALL cells. Thus, PRC2 protects key T cell developmental regulators from DNA hypermethylation in order to keep them primed for activation upon subsequent differentiation phases, while its insufficiency predisposes ETPs to leukemic transformation. These results revealed a previously unrecognized epigenetic switch in response to PRC2 dysfunction and provide the basis for specific rational epigenetic therapy for ETP-ALL with PRC2 insufficiency.

Entities:  

Keywords:  Epigenetics; Hematology; Leukemias; Oncology; T cells

Mesh:

Substances:

Year:  2018        PMID: 30080177      PMCID: PMC6118644          DOI: 10.1172/JCI94645

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

Review 1.  Developmental gene networks: a triathlon on the course to T cell identity.

Authors:  Mary A Yui; Ellen V Rothenberg
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

2.  FBXL10 protects Polycomb-bound genes from hypermethylation.

Authors:  Mathieu Boulard; John R Edwards; Timothy H Bestor
Journal:  Nat Genet       Date:  2015-04-06       Impact factor: 38.330

3.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Authors:  Tobias Neff; Amit U Sinha; Michael J Kluk; Nan Zhu; Mohamed H Khattab; Lauren Stein; Huafeng Xie; Stuart H Orkin; Scott A Armstrong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

4.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

Review 5.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

6.  Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis.

Authors:  L E Cheng; F K Chan; D Cado; A Winoto
Journal:  EMBO J       Date:  1997-04-15       Impact factor: 11.598

7.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

8.  Histone acetylation mediated by Brd1 is crucial for Cd8 gene activation during early thymocyte development.

Authors:  Yuta Mishima; Changshan Wang; Satoru Miyagi; Atsunori Saraya; Hiroyuki Hosokawa; Makiko Mochizuki-Kashio; Yaeko Nakajima-Takagi; Shuhei Koide; Masamitsu Negishi; Goro Sashida; Taku Naito; Tomoyuki Ishikura; Atsushi Onodera; Toshinori Nakayama; Daniel G Tenen; Naoto Yamaguchi; Haruhiko Koseki; Ichiro Taniuchi; Atsushi Iwama
Journal:  Nat Commun       Date:  2014-12-18       Impact factor: 17.694

9.  Age-related epigenetic drift in the pathogenesis of MDS and AML.

Authors:  Shinji Maegawa; Sheryl M Gough; Naoko Watanabe-Okochi; Yue Lu; Nianxiang Zhang; Ryan J Castoro; Marcos R H Estecio; Jaroslav Jelinek; Shoudan Liang; Toshio Kitamura; Peter D Aplan; Jean-Pierre J Issa
Journal:  Genome Res       Date:  2014-01-10       Impact factor: 9.043

10.  Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.

Authors:  Louise M Treanor; Sheng Zhou; Laura Janke; Michelle L Churchman; Zhijun Ma; Taihe Lu; Shann-Ching Chen; Charles G Mullighan; Brian P Sorrentino
Journal:  J Exp Med       Date:  2014-03-31       Impact factor: 14.307

View more
  15 in total

1.  KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.

Authors:  Yusuke Isshiki; Yaeko Nakajima-Takagi; Motohiko Oshima; Kazumasa Aoyama; Mohamed Rizk; Shuhei Kurosawa; Atsunori Saraya; Takashi Kondo; Emiko Sakaida; Chiaki Nakaseko; Koutaro Yokote; Haruhiko Koseki; Atsushi Iwama
Journal:  Blood Adv       Date:  2019-09-10

2.  Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.

Authors:  Pei-Suen Tsou; Phillip Campbell; M Asif Amin; Patrick Coit; Shaylynn Miller; David A Fox; Dinesh Khanna; Amr H Sawalha
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-12       Impact factor: 11.205

3.  EZH2 knockout in oral cavity basal epithelia causes more invasive squamous cell carcinomas.

Authors:  Jorge Baquero; Xiao-Han Tang; Theresa Scognamiglio; Lorraine J Gudas
Journal:  Carcinogenesis       Date:  2021-12-31       Impact factor: 4.741

Review 4.  Deregulated Polycomb functions in myeloproliferative neoplasms.

Authors:  Goro Sashida; Motohiko Oshima; Atsushi Iwama
Journal:  Int J Hematol       Date:  2019-01-31       Impact factor: 2.490

5.  Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.

Authors:  Michael Broux; Cristina Prieto; Sofie Demeyer; Marlies Vanden Bempt; Llucia Alberti-Servera; Inge Lodewijckx; Roel Vandepoel; Nicole Mentens; Olga Gielen; Kris Jacobs; Ellen Geerdens; Carmen Vicente; Charles E de Bock; Jan Cools
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

Review 6.  The Route of Early T Cell Development: Crosstalk between Epigenetic and Transcription Factors.

Authors:  Veronica Della Chiara; Lucia Daxinger; Frank J T Staal
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

7.  Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine.

Authors:  D A Chetverina; D V Lomaev; M M Erokhin
Journal:  Acta Naturae       Date:  2020 Oct-Dec       Impact factor: 1.845

8.  Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia.

Authors:  Juliette Roels; Morgan Thénoz; Bronisława Szarzyńska; Mattias Landfors; Stien De Coninck; Lisa Demoen; Lien Provez; Anna Kuchmiy; Steven Strubbe; Lindy Reunes; Tim Pieters; Filip Matthijssens; Wouter Van Loocke; Büşra Erarslan-Uysal; Paulina Richter-Pechańska; Ken Declerck; Tim Lammens; Barbara De Moerloose; Dieter Deforce; Filip Van Nieuwerburgh; Laurence C Cheung; Rishi S Kotecha; Marc R Mansour; Bart Ghesquière; Guy Van Camp; Wim Vanden Berghe; Jerzy R Kowalczyk; Tomasz Szczepański; Utpal P Davé; Andreas E Kulozik; Steven Goossens; David J Curtis; Tom Taghon; Małgorzata Dawidowska; Sofie Degerman; Pieter Van Vlierberghe
Journal:  Blood Cancer Discov       Date:  2020-09-23

9.  Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia.

Authors:  Yizhen Li; Wentao Yang; Meenakshi Devidas; Stuart S Winter; Chimene Kesserwan; Wenjian Yang; Kimberly P Dunsmore; Colton Smith; Maoxiang Qian; Xujie Zhao; Ranran Zhang; Julie M Gastier-Foster; Elizabeth A Raetz; William L Carroll; Chunliang Li; Paul P Liu; Karen R Rabin; Takaomi Sanda; Charles G Mullighan; Kim E Nichols; William E Evans; Ching-Hon Pui; Stephen P Hunger; David T Teachey; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Clin Invest       Date:  2021-06-24       Impact factor: 14.808

Review 10.  EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.

Authors:  Boheng Li; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.